Publications (PubMed)

• Rethinking the use of germline CHEK2 mutation as a marker for PARP inhibitor sensitivity.Hayman TJ. JNCI Cancer Spectr. 2024 Jul 1. PMID: 38950525.
• Radioresistant Pulmonary Oligometastatic and Oligoprogressive Lesions From Nonlung Primaries: Impact of Histology and Dose-Fractionation on Local Control After Radiation Therapy.Verma N, Laird JH, Moore NS, Hayman TJ, Housri N, Peters GW, Knowlton CA, Jairam V, Campbell AM, Park HS. Adv Radiat Oncol. 2024 Jun; 2024 Mar 21. PMID: 38699671.
• Dose-Volume Predictors of Radiation Pneumonitis After Thoracic Hypofractionated Radiation Therapy.Sasse A, Oh P, Saeed N, Yang DX, Hayman TJ, Knowlton CA, Peters GW, Campbell A, Laird J, Housri N, Park HS. Pract Radiat Oncol. 2024 Mar-Apr; 2023 Nov 19. PMID: 37984711.
• STING Agonists in Head and Neck Squamous Cell Carcinoma.Wallington DG, Contessa JN, Hayman TJ. Cancer J. 2022 Sep-Oct 01. PMID: 36165729.
• Regulation of the Cell-Intrinsic DNA Damage Response by the Innate Immune Machinery.Hayman TJ, Glazer PM. Int J Mol Sci. 2021 Nov 25; 2021 Nov 25. PMID: 34884568.
• Combinations of immunotherapy and radiation therapy in head and neck squamous cell carcinoma: a narrative review.Hayman TJ, Bhatia AK, Jethwa KR, Young MR, Park HS. Transl Cancer Res. 2021 May. PMID: 35116571.
• STING enhances cell death through regulation of reactive oxygen species and DNA damage.Hayman TJ, Baro M, MacNeil T, Phoomak C, Aung TN, Cui W, Leach K, Iyer R, Challa S, Sandoval-Schaefer T, Burtness BA, Rimm DL, Contessa JN. Nat Commun. 2021 Apr 19; 2021 Apr 19. PMID: 33875663.
• The translocon-associated protein (TRAP) complex regulates quality control of N-linked glycosylation during ER stress.Phoomak C, Cui W, Hayman TJ, Yu SH, Zhao P, Wells L, Steet R, Contessa JN. Sci Adv. 2021 Jan; 2021 Jan 15. PMID: 33523898.
• CDKN2A Copy Number Loss Is an Independent Prognostic Factor in HPV-Negative Head and Neck Squamous Cell Carcinoma.Chen WS, Bindra RS, Mo A, Hayman T, Husain Z, Contessa JN, Gaffney SG, Townsend JP, Yu JB. Front Oncol. 2018; 2018 Apr 4. PMID: 29670856.
• Outcomes of resected pancreatic cancer in patients age ≥70.Hayman TJ, Strom T, Springett GM, Balducci L, Hoffe SE, Meredith KL, Hodul P, Malafa M, Shridhar R. J Gastrointest Oncol. 2015 Oct. PMID: 26487943.
• The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.Kahn J, Hayman TJ, Jamal M, Rath BH, Kramp T, Camphausen K, Tofilon PJ. Neuro Oncol. 2014 Jan; 2013 Dec 4. PMID: 24311635.
• The ATP-competitive mTOR inhibitor INK128 enhances in vitro and in vivo radiosensitivity of pancreatic carcinoma cells.Hayman TJ, Wahba A, Rath BH, Bae H, Kramp T, Shankavaram UT, Camphausen K, Tofilon PJ. Clin Cancer Res. 2014 Jan 1; 2013 Nov 6. PMID: 24198241.
• Competitive but Not Allosteric mTOR Kinase Inhibition Enhances Tumor Cell Radiosensitivity.Hayman TJ, Kramp T, Kahn J, Jamal M, Camphausen K, Tofilon PJ. Transl Oncol. 2013 Jun; 2013 Jun 1. PMID: 23730416.
• Body mass index and survival in esophageal adenocarcinoma treated with chemoradiotherapy followed by esophagectomy.Shridhar R, Hayman T, Hoffe SE, Weber J, Almhanna K, Chuong M, Karl RC, Meredith KL. J Gastrointest Surg. 2012 Jul; 2012 Mar 8. PMID: 22399271.
• Translation initiation factor eIF4E is a target for tumor cell radiosensitization.Hayman TJ, Williams ES, Jamal M, Shankavaram UT, Camphausen K, Tofilon PJ. Cancer Res. 2012 May 1; 2012 Mar 7. PMID: 22397984.
• Comparison of 1-, 2-, and 3-Dimensional Tumor Response Assessment After Neoadjuvant GTX-RT in Borderline-Resectable Pancreatic Cancer.Chuong MD, Hayman TJ, Patel MR, Russell MS, Malafa MP, Hodul PJ, Springett GM, Choi J, Shridhar R, Hoffe SE. Gastrointest Cancer Res. 2011 Jul. PMID: 22368736.